In the current market at the time of writing, Unity Biotechnology Inc. (UBX) shares were trading at $4.71, up 5.37%. The UBX stock price closed at $4.47 in the previous session. Volume on UBX stock fell to 0.47 million shares, less than the 50-day average of 0.55 million shares. Within the past week, UBX shares have risen by 3.00%, following a drop of -50.11% over the past 12 months.

UBX stock has lost -27.79% over the past three months, and -14.69% over the past six months. Furthermore, UBX has a market capitalization of $246.79 million and 54.17 million outstanding shares. Following a positive phase I clinical trial announcement, UBX stock is rising.

What is the purpose of UBX’s trial?

A new class of therapeutics is being developed by UNITY to prevent, slow down, or reverse diseases of aging. UBX is currently developing medicines that target senescent cells which will have a transformative effect on diseases related to aging.

A Phase 1 safety study of UBX1325 involving a combination of vegf inhibitors and monoclonal antibodies was announced today by Unity Biotechnology for early-stage DME or wet AMD patients for whom anti-VEGF treatment was no longer considered effective.

• As part of UBX’s Phase 2a clinical study, the first patient with DME has been dosed with UBX1325.
• UBX anticipates receiving trial results in the first half of 2022.
• A Phase 1 study with advanced wet AMD is also being conducted by UBX so that more data can be collected to support a Phase 2a study in wet AMD.
• It is hoped that the results of these studies will inform clinicians about UBX1325’s efficacy across a wider spectrum of patients, including those who are refractory to anti-VEGF therapy.
• Twelve patients with advanced DME or wet AMD, unresponsive to anti-VEGF therapies, were included in the UBX Phase 1, first-in-human, open-label study.
• These results support further clinical development of UBX1325 in this patient population, which showed a favorable acute safety profile.
• Two nonserious but nondrug-related adverse events were reported, but no dose-limiting toxicity was observed.
• Further, patients treated with UBX1325 saw improvement in sight and retinal structure.

What UBX is expecting further?

Unity Biotechnology (UBX) candidate works entirely differently, by targeting a completely different mechanism in the retinal and choroidal vasculature, which is a possible root cause of disease progression. With this method, UBX1325 would be a valuable alternative to anti-VEGF treatments. In the coming year, Unity (UBX) will be reporting a number of important data readouts that will bolster its knowledge of the optimal treatment regimen and combination of UBX1325 and DME.